Biogen pays up to $1B for secretive San Diego biotech RayThera, gaining three undisclosed anti-inflammatory candidates to expand in I&I.
Biogen CEO Chris Viehbacher at the Financial Times summit in New York.
June 17, 2026 08:43 PM EDT
Deals
Biogen makes up to $1B deal for secretive anti-inflammatory biotech
Kyle LaHucik
Biogen acquires RayThera in a deal worth up to $1 billion, adding early-stage immunology assets as it expands beyond Alzheimer's…
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.
Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio of rare-disease…
Biogen pauses or cancels most R&D programs from its $5.6B Apellis buyout and lays off staff, keeping its focus on Empaveli and…
With increased sales of its newer drugs compensating for declining revenues from its multiple sclerosis (MS) portfolio, Biogen is…
One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the strength of…
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline - Biogen (NASDAQ:BIIB)
Biogen adds more immune drugs in $1B buyout of secretive startup Raythera
AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs
AbbVie to buy Apogee Therapeutics in nearly $11B deal
Another big deal, another sign biotech M&A is back
AbbVie Goes On The Offensive With $10.9 Billion Takeover
Bionyra brings in $165M for next-generation immune drugs
AbbVie ultima la compra de la 'biotech' Apogee por 9.500 millones
